30 Percent RA Patients Refractory To Anti-TNFs Achieve Disease Remission With Tocilizumab Plus Metho

Tocilizumab plus methotrexate showed significant clinical improvements in efficacy and safety in patients with moderate to severe rheumatoid arthritis, who had not adequately responded to anti-tumour necrosis factor (anti-TNF) therapy. Tocilizumab, an anti-interleukin (IL)-6 receptor monoclonal antibody, was demonstrated to be effective irrespective of the number of, or the most recently-failed anti-TNF treatments.

Read the whole article on Science Daily

More from Science Daily